Onsdag 8 Oktober | 03:18:38 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-16 08:30 Bokslutskommuniké 2025
2025-11-03 08:30 Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder produkter som Dosell, en läkemedelsrobot, och SaaS-lösningen Pilloxa, en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group har sitt huvudkontor i Stockholm.
2025-09-30 21:15:00

iZafe Group AB (publ) today signed an agreement to acquire its exclusive distributor in the Netherlands, Thuisapparatuur Nederland B.V., which has built a rapidly growing Dosell business in Europe’s largest market for medication dispensers.

The transaction strengthens growth, margins and cash flow and is carried out without dilution for shareholders or the need for external financing. Through the acquisition, iZafe estimates that the ARR target of SEK 10 million can already be achieved during Q4 2025, earlier than the original projection of year-end 2025. The deal also increases the likelihood of reaching the ARR targets for coming years at a faster pace.

Since its founding in 2023, Thuisapparatuur has worked exclusively with the distribution of Dosell and has built a strong local presence in the Netherlands. The company will now become a wholly owned subsidiary within the iZafe Group under the new name Dosell B.V., meaning that the distribution of Dosell in the Dutch market will henceforth be handled directly by iZafe, thereby capturing the full revenue from this important market.

Transaction terms

  • Purchase Price: EUR 1.55 million, which includes the assumption of the company’s existing loan.
  • Payment terms: The Purchase Price will be settled in seven instalments during the period July 31, 2026 – July 31, 2029. The first two instalments will each amount to 20% of the Purchase Price, while the remaining five will be evenly distributed over the subsequent payment dates.
  • Security: In the event of non-payment, the debt may, as a last resort, be converted into shares in iZafe Group under agreed terms.
  • Closing: Has taken place today in connection with the signing of the agreement.
  • Final obligations: Upon completion of all seven instalments, iZafe Group will have no further payment obligations to the seller.

The transaction is not expected to have a negative impact on iZafe’s liquidity, as the Purchase Price is projected to be fully financed through future cash flows from both the existing and the acquired business. The Purchase Price of EUR 1.55 million largely corresponds to the capital invested to date in Thuisapparatuur, which iZafe considers a sound valuation relative to the company’s established growth and strong market position. It should be noted that Thuisapparatuur has a cash position of approximately EUR 250k included in the acquisition. Excluding this cash, the Purchase Price corresponds to approximately EUR 1.30 million.

Dosell contributes to safer medication management, reduced medication errors and frees up time for healthcare staff – needs that are growing rapidly in line with an aging population. The product has documented high customer satisfaction and generates clear efficiency gains.

The Netherlands is Europe’s largest market for pouch-packed medication, with over 600,000 people receiving their medicine in pouches – the same format Dosell is designed for. The country is also the European market that has advanced the furthest in adopting medication dispensers, with around 17,000 active units, and the market where iZafe is currently growing the fastest.

In 2024, Thuisapparatuur’s revenue amounted to approximately SEK 0.75 million. For the period January–September 2025, the company recorded an average monthly growth rate of approximately 16%. As of September 30, 2025, Thuisapparatuur’s total Annual Recurring Revenue (ARR) amounted to approximately SEK 4.2 million. Following the acquisition, 100% of future revenues from the sale of Dosell in the Netherlands will accrue to iZafe Group, strengthening recurring revenues, improving margins and increasing cash flow.

This is a strategically important step that gives us direct control over our largest and fastest-growing market. The entire Dutch organization has for several years worked exclusively with Dosell and is already deeply integrated into our product, business model and customer base. This makes it a natural next step for both them and us. Together we strengthen our business, improve profitability and lay the foundation for continued growth across Europe. Our core strategy of expanding through strong partnerships across Europe remains firm, but in the Netherlands it is right that we take the lead ourselves, says Anders Segerström, CEO of iZafe Group.